The NIH Clinical Center research team, led by Dr. Joseph Frank, will labelthe MenSCs with iron oxide nanoparticles, which will make it possible to trackthe distribution of the MenSCs in the body using magnetic resonance imaging(MRI). The ability to use MRI to monitor the migration of the MenSCs mayprovide the basis for determining the future utility of MenSCs in thetreatment of disease.

"We know that the MenSCs are capable of differentiating into differentcell types, and that they have the ability to divide rapidly," said JulieAllickson, Ph.D., Vice President of Laboratory Operations and Research andDevelopment at Cryo-Cell. "The study may provide the basis for determiningfuture use of these cells to treat diseases."

Clinical non-invasive imaging techniques that allow for long term trackingof stem cells in vivo do not currently exist. The Experimental NeuroimagingSection of Radiology and Imaging Sciences at the NIH Clinical Center hasdeveloped techniques to label stem cells with the FDA approved agent,ferumoxides (FE), which is commonly used as a contrast agent with magneticresonance (MR) imaging. By using FE, researchers in the ExperimentalNeuroimaging Section of the LDRR are able to track the temporal and spatialmigration by MRI.

Dr. Frank and his colleagues in the Experimental Neuroimaging Section ofRadiology and Imaging Sciences will evaluate the labeling efficiency of MenSCsto determine if there is any alteration in differentiation potential,proliferative capacity, metabolic alterations, apoptosis rate and/or anincrease in iron content of the tracked cells compared to unlabeled cells.

Following the in vitro evaluation of FEPro (ferumoxides complexed toprotamine sulfate) labeled endometrial cell function, if the MenSCs are notaltered by FEPro labeling, a series of in vivo MRI studies will be conductedin rodent tumor models to determine if the magnetically labeled cells willmigrate to and integrate into the tumor. Further studies may be added thatwill explore the therapeutic uses of MenSCs at the molecular level, as genetherapy or delivery vehicles for nanotherapeutic chemotherapeutic agents totreat cancer if the present research supports such studies.

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL)

Based in Oldsmar, Florida, with over 160,000 clients worldwide, Cryo-Cellis one of the largest and most established family cord blood banks. ISO9001:2000 certified and accredited by the AABB, Cryo-Cell operates in astate-of-the-art Good Manufacturing Practice and Good Tissue Practice(cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTCBulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL(1-800-786-7235) or visit http://www.cryo-cell.com or http://www.celle.com.

Forward-Looking Statement

Statements wherein the terms "believes", "intends", "projects" or"expects" as used are intended to reflect "forward-looking statements" of theCompany. The information contained herein is subject to various risks,uncertainties and other factors that could cause actual results to differmaterially from the results anticipated in such forward-looking statements orparagraphs, many of which are outside the control of the Company. Theseuncertainties and other factors include the uncertainty of domestic andinternational market acceptance of any potential service offerings relating totypes of stem cells other than cord blood stem cells, including the C'elleservice, given that menstrual stem cells and other new stem cells have not yetbeen used in human therapies, and treatment applications using such stem cellsare not likely to be developed and commercialized for many years and aresubject to further research and development; the need for additionaldevelopment and testing before determining the ultimate commercial value ofthe Company's intellectual property relating to the menstrual stem cells; theneed to complete certain developments, including completion of clinicalvalidation and testing, before any new process other than C'elle can becommercialized, and the Company's development of its final business andeconomic model in offering any such service; any adverse effect or limitationscaused by recent increases in government regulation of stem cell storagefacilities; any increased competition in our business; any decrease orslowdown in the number of people seeking to store umbilical cord blood stemcells or decrease in the number of people paying annual storage fees; anyadverse impacts on our revenue or operating margins due to the costsassociated with increased growth in our business, including the possibility ofunanticipated costs relating to the operation of our new facility; anytechnological breakthrough or medical breakthrough that would render theCompany's business of stem cell preservation obsolete; any material failure ormalfunction in our storage facilities; any natural disaster such as a tornado,other disaster (fire) or act of terrorism that adversely affects storedspecimens; the costs associated with defending or prosecuting litigationmatters and any material adverse result from such matters; decreases in assetvaluations; any continued negative effect from adverse publicity in the pastyear regarding the Company's business operations; any negative consequencesresulting from deriving, shipping and storing specimens at a second location;and other risks and uncertainties. The foregoing list is not exhaustive, andthe Company disclaims any obligations to subsequently revise anyforward-looking statements to reflect events or circumstances after the dateof such statements. Readers should carefully review the risk factors describedin other documents the Company files from time to time with the Securities andExchange Commission, including the most recent Annual Report on Form 10-KSB,Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed bythe Company.

Disclaimer: NO ENDORSEMENT OF ANY ORGANIZATION, PRODUCT OR SERVICEMENTIONED IN THIS ARTICLE IS INTENDED BY THE NATIONAL INSTITUTES OF HEALTH ORITS EMPLOYEES OR SHOULD BE INFERRED.

Contact: General Media Inquiries Kristin O'Neill 312-233-1295 kristin.oneill@edelman.com Financial Media Inquiries Mona Walsh 212-704-4598 mona.walsh@edelman.comSOURCE Cryo-Cell International Inc.